von Hendrik Fokken ; Julian Waclawski ; Nadine Kattre ; Arnold Kloos ; Sebastian Müller ; Max Ettinger ; Tim Kacprowski ; Michael Heuser ; Michael Maetzig ; Adrian Schwarzer
Impressum: Diese Publikation erscheint anlässlich der Ausstellungen 'Michael Müller: Mögliche und unmögliche Bilder' Museum im Kulturspeicher Würzburg 26. November 2022-19. März 2023 und 'Michael Müller: Am Abgrund der Bilder' St. Matthäus-Kirche, Berlin 22. April-3. September 2023
Ausstellungskatalog -- Museum im Kulturspeicher Würzburg -- 2022-2023 -- Würzburg; Ausstellungskatalog -- 2023 -- BerlinRichter, GerhardRezeptionMüller, MichaelKünstlerMalerIngelheim am RheinBerlin1970-AuswirkungFortlebenKünstler1953-2014
"Diese Publikation erscheint anlässlich der Ausstellung Michael Müller: Der geschenkte Tag. Kastor & Polydeukes. Städel Museum, Frankfurt am Main 14. Oktober 2022 - 23. April 2023" - Impressum
Ausstellungskatalog -- Städel Museum -- 14.10.2022-23.04.2023 -- Frankfurt am Main; InterviewMüller, MichaelKünstlerMalerIngelheim am RheinBerlin1970-
Ernstes Spiel - Catalogue Raisonné / Michael Müller
Ernstes Spiel - Catalogue Raisonné / Michael Müller ; volume 1,4
von Martin Metzenmacher ; Frank Griesinger ; Horst-Dieter Hummel ; Corinna Elender ; Harald Schäfer ; Maike de Wit ; Ulrich Kaiser ; Jens Kern ; Martina Jänicke ; Lisa Spring ; Stefan Zacharias ; Anja Kaiser-Osterhues ; Annika Groth ; Annette Hipper ; Gregor Zaun ; Steffen Dörfel ; Björn Güldenzoph ; Lothar Müller ; Jens Uhlig ; Michael Thomas ; Martin Sebastian ; Wilfried E. E. Eberhardt
von Julian Müller ; Karin Nentwich ; Artur Berkovitz ; Elena Ene ; Kai Sonne ; Vitaly Zhuravlev ; Ivaylo Chakarov ; Sebastian Barth ; Christian Waechter ; Michael Behnes ; Philipp Halbfaß ; Thomas Deneke
Pulmonary vein isolation using radiofrequency ablation is an effective treatment option for patients with symptomatic atrial fibrillation (AF). Application of high power over a short period of time (HPSD) is reported to create more efficient lesions and may prevent collateral thermal oesophageal injury. This study aims to compare efficacy and safety of two different HPSD ablation approaches using different ablation index settings.Consecutive patients undergoing AF ablation with HPSD (50 W; ablation index-guided) using the ThermoCool SmartTouch SF catheter were included. Patients were grouped by ablation protocol: ablation with target ablation index (AI) of 400 on the anterior left atrial wall vs. 300 at the posterior left atrial wall (AI 400/300) or AI 450/350 was performed upon the operator’s preference and compared. Peri-procedural parameters and complications were recorded, and incidences of endoscopically detected thermal oesophageal lesions (EDEL) analysed. Recurrence rates after a mean follow-up of 25 ± 7 months and reconnection patterns in patients undergoing redo procedures were investigated. A total of 795 patients (67 ± 10 years; 58% male; 48% paroxysmal AF) underwent a first AF ablation with HPSD (211 in group AI 400/300 and 584 in group 450/350). Median procedure time was 82.9 ± 24.6 min with longer ablation times in patients with target AI 400/300 due to higher intraprocedural reconnection rates, increased box lesions, and additional right atrial isthmus ablations. One hundred three patients (16%) underwent a redo procedure during follow-up documented comparable pulmonary vein (PV) reconnection among groups. Multivariate predictors of AF recurrence were age, left atrium (LA) size, persistent AF, and extra-PV ablation targets.High-power short-duration AF ablation with target AI of 400 for non-posterior wall and 300 for posterior wall lesions resulted in comparable long-term results compared to higher AI (450/350) ablations with significantly lower risk for thermal oesophageal lesions. Older age, larger LA size, persistent AF, and extra-PV ablation targets were identified in a multivariate analysis as independent risk factors for recurrences of atrial arrhythmias.
von Julian Müller ; Ivaylo Chakarov ; Philipp Halbfaß ; Karin Nentwich ; Elena Ene ; Artur Berkovitz ; Kai Sonne ; Sebastian Barth ; Christian Waechter ; Tobias Schupp ; Michael Behnes ; Ibrahim Akın ; Thomas Deneke
Background: Electrical storm (ES) represents a serious heart rhythm disorder. This study investigates the impact of ES on acute ablation success and long-term outcomes after VT ablation compared to non-ES patients. Methods: In this large single-centre study, patients presenting with ES and undergoing VT ablation from June 2018 to April 2021 were compared to patients undergoing VT ablation due to ventricular tachyarrhythmias but without ES. The primary prognostic outcome was VT recurrence, and secondary endpoints were rehospitalization rates and cardiovascular mortality, all after a median follow-up of 22 months. Results: A total of 311 patients underwent a first VT ablation due to ventricular tachyarrhythmias and were included (63 ± 14 years; 86% male). Of these, 108 presented with ES. In the ES cohort, dilated cardiomyopathy as underlying heart disease was significantly higher (p = 0.008). Major complications were equal across both groups (all p > 0.05). Ablation of the clinical VT was achieved in 94% of all patients (p > 0.05). Noninducibility of any VT was achieved in 91% without ES and in 76% with ES (p = 0.001). Patients with ES revealed increased VT recurrence rates during follow-up (65% vs. 40%; log rank p = 0.001; HR 1.841, 95% CI 1.289-2.628; p = 0.001). Furthermore, ES patients suffered from increased rehospitalization rates (73% vs. 48%; log rank p = 0.001; HR 1.948, 95% CI 1.415-2.682; p = 0.001) and cardiovascular mortality (18% vs. 9%; log rank p = 0.045; HR 1.948, 95% CI 1.004-3.780; p = 0.049). After multivariable adjustment, ES was a strong independent predictor of VT recurrence and rehospitalization rates, but not for mortality. In a propensity score-matched cohort, patients with ES still had a higher risk of VT recurrences and rehospitalizations compared to non-ES patients. Conclusions: VT ablation in patients with ES is challenging and these patients reveal the highest risk for recurrent VTs, rehospitalization and cardiovascular mortality. These patients need close follow-ups and optimal guideline-directed therapy.
Journal of Clinical Medicine Basel : MDPI, 2012 12(2023), 7 vom: Apr., Seite 1-15 Online-Ressource